| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
188,370,000 |
| Market
Cap: |
16.70(B) |
| Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
| 52
Week Range: |
$76.22 - $99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 811 |
| Guru Rank Value : 0.9 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
3,625 |
| Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
159,588 |
275,693 |
319,053 |
656,089 |
| Total Sell Value |
$13,270,852 |
$23,760,160 |
$27,661,182 |
$61,420,002 |
| Total People Sold |
5 |
6 |
7 |
7 |
| Total Sell Transactions |
10 |
21 |
27 |
56 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2023-04-10 |
4 |
AS |
$99.56 |
$995,600 |
D/D |
(10,000) |
425,896 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2023-04-10 |
4 |
OE |
$67.81 |
$678,100 |
D/D |
10,000 |
435,896 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2023-04-06 |
4 |
AS |
$96.13 |
$961,300 |
D/D |
(10,000) |
425,896 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2023-04-06 |
4 |
OE |
$67.81 |
$678,100 |
D/D |
10,000 |
435,896 |
|
- |
|
| Davis George Eric |
EVP, Chief Legal Officer |
• – – |
2023-03-16 |
4 |
D |
$93.41 |
$1,864,183 |
D/D |
(19,957) |
80,367 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2023-03-16 |
4 |
D |
$93.41 |
$8,278,274 |
D/D |
(88,623) |
425,896 |
|
- |
|
| Fuchs Henry J |
President, Worldwide R&D |
• – – |
2023-03-16 |
4 |
D |
$93.41 |
$3,362,760 |
D/D |
(36,000) |
188,187 |
|
- |
|
| Mueller Brian |
EVP, Chief Financial Officer |
• – – |
2023-03-16 |
4 |
D |
$93.41 |
$371,118 |
D/D |
(3,973) |
55,585 |
|
- |
|
| Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
• – – |
2023-03-16 |
4 |
D |
$93.41 |
$1,915,839 |
D/D |
(20,510) |
65,486 |
|
- |
|
| Davis George Eric |
EVP, Chief Legal Officer |
• – – |
2023-03-15 |
4 |
D |
$87.74 |
$265,414 |
D/D |
(3,025) |
100,324 |
|
- |
|
| Davis George Eric |
EVP, Chief Legal Officer |
• – – |
2023-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
8,900 |
103,349 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2023-03-15 |
4 |
D |
$87.74 |
$828,002 |
D/D |
(9,437) |
514,519 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2023-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
36,100 |
523,956 |
|
- |
|
| Guyer Charles Greg |
EVP, Chief Technical Officer |
• – – |
2023-03-15 |
4 |
D |
$87.74 |
$162,845 |
D/D |
(1,856) |
49,464 |
|
- |
|
| Guyer Charles Greg |
EVP, Chief Technical Officer |
• – – |
2023-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
8,900 |
51,320 |
|
- |
|
| Fuchs Henry J |
President, Worldwide R&D |
• – – |
2023-03-15 |
4 |
D |
$87.74 |
$421,064 |
D/D |
(4,799) |
224,187 |
|
- |
|
| Fuchs Henry J |
President, Worldwide R&D |
• – – |
2023-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
16,840 |
228,986 |
|
- |
|
| Burkhart Erin |
GVP, Chief Accounting Officer |
• – – |
2023-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,760 |
14,890 |
|
- |
|
| Mueller Brian |
EVP, Chief Financial Officer |
• – – |
2023-03-15 |
4 |
D |
$87.74 |
$237,600 |
D/D |
(2,708) |
59,558 |
|
- |
|
| Mueller Brian |
EVP, Chief Financial Officer |
• – – |
2023-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
9,630 |
62,266 |
|
- |
|
| Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
• – – |
2023-03-15 |
4 |
D |
$87.74 |
$348,416 |
D/D |
(3,971) |
85,996 |
|
- |
|
| Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
• – – |
2023-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
10,110 |
89,967 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2023-03-13 |
4 |
AS |
$90.45 |
$723,600 |
D/D |
(8,000) |
487,856 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2023-03-13 |
4 |
OE |
$67.81 |
$542,480 |
D/D |
8,000 |
495,856 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2023-03-10 |
4 |
AS |
$92.28 |
$1,384,200 |
D/D |
(15,000) |
487,856 |
|
- |
|
2582 Records found
|
|
Page 6 of 104 |
|
|
1.44 (1.6%) 
